>my question/concern is whether or not transgenically-derived biosimiliars, if that is where GTC is pointed, are going to have a greater headwind than other biosimiliars<
Possible, but I see no indications that this will be the case. As more transgenically-produced drugs are approved, the novelty will wear off and these drugs will IMO increasingly be viewed as simply recombinant biologics.
Market Data 
Markets 
AI
